Vir Biotechnology (VIR) Stock Price, News & Analysis

Company Overview

Vir Biotechnology, Inc. is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis. Vir entered into a notable collaboration with GlaxoSmithKline to develop monoclonal antibody therapies against SARS-CoV-2. Beyond its lead COVID-19 antibody program, Vir’s research focuses on next‐generation antiviral treatments and vaccines, employing deep sequencing and single-cell analysis to accelerate discovery. Preclinical and clinical trials are underway across multiple indications, reflecting the company’s commitment to addressing unmet medical needs in infectious diseases.

Founded in 2017, Vir Biotechnology is headquartered in San Francisco, California, and operates research and development facilities in the United States and Europe. The company’s management team comprises experienced leaders in biotechnology and infectious disease research, driving strategic partnerships with academic institutions and global health organizations. Through its integrated platform and collaborative model, Vir aims to rapidly translate scientific insights into therapies that can improve outcomes for patients worldwide.

Key Stats

• Today's Range: $9.90 to $10.45
• 50-Day Range: $7.43 to $11.09
• 52-Week Range: $4.16 to $11.66
• Volume: 1.04 million shs
• Average Volume: 1.76 million shs
• Market Capitalization: $1.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.38
• Consensus Rating: Moderate Buy

Vir Biotechnology Stock Analysis - MarketRank™

Vir Biotechnology scored higher than 65% of companies evaluated by MarketBeat, and ranked 256th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Vir Biotechnology has a consensus price target of $20.38, representing about 103.5% upside from its current price of $10.01.

Amount of Analyst Coverage

Vir Biotechnology has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vir Biotechnology are expected to decrease in the coming year, from ($1.97) to ($2.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vir Biotechnology is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vir Biotechnology is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vir Biotechnology has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.41% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 8.79.

Change versus previous month

Short interest in Vir Biotechnology has recently decreased by 0.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vir Biotechnology does not currently pay a dividend.

Dividend Growth

Vir Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.17

News Sentiment

Vir Biotechnology has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.

Search Interest

10 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

6 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,377,698.00 in company stock.

Percentage Held by Insiders

16.00% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIR Stock Analysis - Frequently Asked Questions

How have VIR shares performed this year?

Vir Biotechnology's stock was trading at $6.03 on January 1st, 2026. Since then, VIR shares have increased by 66.0% and is now trading at $10.01.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Monday, February, 23rd. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. The firm's quarterly revenue was up 417.8% compared to the same quarter last year.
Read the conference call transcript.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $150 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,142,858 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's top institutional investors include Pictet Asset Management Holding SA (0.92%), Candriam S.C.A. (0.70%), Bank of New York Mellon Corp (0.36%) and Principal Financial Group Inc. (0.34%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Jason O'byrne, Mark Eisner, Ann M Hanly, Verneuil Vanina De, Steven J Rice, Brent Sabatini, Janet Napolitano and Saira Ramasastry.
View institutional ownership trends.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vir Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V).

Company Calendar

• Last Earnings: 2/23/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIR
• CIK: 1706431
• Web: www.vir.bio
• Phone: 415-906-4324
• Fax: N/A
• Employees: 580
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vir Biotechnology: $20.38
• High Price Target: $30.00
• Low Price Target: $14.00
• Potential Upside/Downside: +103.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$437.99 million
• Net Margins: -638.88%
• Pretax Margin: -638.56%
• Return on Equity: -49.31%
• Return on Assets: -38.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $68.56 million
• Price / Sales: 23.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.50 per share
• Price / Book: 1.82

Miscellaneous

• Outstanding Shares: 161,230,000
• Free Float: 135,437,000
• Market Cap: $1.61 billion
• Optionable: Optionable
• Beta: 1.70